Literature DB >> 16371729

CASH (Chemotherapy-Associated Steatohepatitis) costs.

Yuman Fong, David J Bentrem.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16371729      PMCID： PMC1449964          DOI： 10.1097/01.sla.0000193599.57858.9b

Source DB:  PubMed          Journal:  Ann Surg        ISSN： 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  10 in total

1.  Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.

Authors:  Mehdi Karoui; Christophe Penna; Mohamed Amin-Hashem; Emmanuel Mitry; Stephane Benoist; Brigitte Franc; Philippe Rougier; Bernard Nordlinger
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

2.  Qualitative assessment of liver for fatty infiltration on contrast-enhanced CT: is muscle a better standard of reference than spleen?

Authors:  D M Panicek; C S Giess; L H Schwartz
Journal:  J Comput Assist Tomogr       Date:  1997 Sep-Oct       Impact factor: 1.826

Review 3.  Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma.

Authors:  Gregory D Leonard; Baruch Brenner; Nancy E Kemeny
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

4.  Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.

Authors:  Felix G Fernandez; John Ritter; J Wendell Goodwin; David C Linehan; William G Hawkins; Steven M Strasberg
Journal:  J Am Coll Surg       Date:  2005-06       Impact factor: 6.113

5.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.

Authors:  Y Fong; J Fortner; R L Sun; M F Brennan; L H Blumgart
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

6.  Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.

Authors:  René Adam; Valérie Delvart; Gérard Pascal; Adrian Valeanu; Denis Castaing; Daniel Azoulay; Sylvie Giacchetti; Bernard Paule; Francis Kunstlinger; Odile Ghémard; Francis Levi; Henri Bismuth
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

7.  Preoperative portal vein embolization for extended hepatectomy.

Authors:  Alan W Hemming; Alan I Reed; Richard J Howard; Shiro Fujita; Steven N Hochwald; James G Caridi; Irvin F Hawkins; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2003-05       Impact factor: 12.969

8.  Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report.

Authors:  M Makuuchi; B L Thai; K Takayasu; T Takayama; T Kosuge; P Gunvén; S Yamazaki; H Hasegawa; H Ozaki
Journal:  Surgery       Date:  1990-05       Impact factor: 3.982

9.  Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy.

Authors:  Alexander A Parikh; Bernhard Gentner; Tsung-Teh Wu; Steven A Curley; Lee M Ellis; Jean-Nicolas Vauthey
Journal:  J Gastrointest Surg       Date:  2003-12       Impact factor: 3.267

10.  Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer.

Authors:  P D Peppercorn; R H Reznek; P Wilson; M L Slevin; R K Gupta
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640
  10 in total
  29 in total

Review 1.  Post-hepatectomy liver failure.

Authors:  Rondi Kauffmann; Yuman Fong
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

Review 2.  Drug-induced steatohepatitis.

Authors:  Ajit Dash; Robert A Figler; Arun J Sanyal; Brian R Wamhoff
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-27       Impact factor: 4.481

3.  Patient selection for hepatic resection for metastatic colorectal cancer.

Authors:  Matthew J Weiss; Michael I D'Angelica
Journal:  J Gastrointest Oncol       Date:  2012-03

4.  Perioperative management of hepatic resection.

Authors:  Andrew J Page; David A Kooby
Journal:  J Gastrointest Oncol       Date:  2012-03

5.  Protective effect of hydrogen-rich water on liver function of colorectal cancer patients treated with mFOLFOX6 chemotherapy.

Authors:  Qingxi Yang; Guangdong Ji; Rongtao Pan; Yinghui Zhao; Peng Yan
Journal:  Mol Clin Oncol       Date:  2017-09-01

6.  Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases?

Authors:  Nir Lubezky; Ravit Geva; Einat Shmueli; Richard Nakache; Joseph M Klausner; Arie Figer; Menahem Ben-Haim
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

7.  Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study.

Authors:  Mahfud Mahfud; Stefan Breitenstein; Ashraf Mohammad El-Badry; Milo Puhan; Andreas Rickenbacher; Panagiotis Samaras; Patrick Pessaux; Santiago Lopez-Ben; Daniel Jaeck; Joan Figueras; Pierre Alain-Clavien
Journal:  World J Surg       Date:  2010-01       Impact factor: 3.352

Review 8.  Surgery for colorectal liver metastases.

Authors:  J N Primrose
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

9.  Nodular regenerative hyperplasia secondary to neoadjuvant chemotherapy for colorectal liver metastases.

Authors:  Maartje A J van den Broek; Steven W M Olde Damink; Ann Driessen; Cornelis H C Dejong; Marc H A Bemelmans
Journal:  Case Rep Med       Date:  2009-11-22

10.  The case for selective use of pre-operative chemotherapy for hepatic colorectal metastases: more is not always better.

Authors:  Giorgos Karakousis; Yuman Fong
Journal:  Ann Surg Oncol       Date:  2009-06-10       Impact factor: 5.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.